Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world cell-free circulating tumor DNA (ctDNA) analysis identifies CDK4/6 inhibitor resistance and tumor evolution in HR+ advanced breast cancer.

NPJ breast cancer·2026
Same author

Evidence for a Spectral Break or Curvature in the Spectrum of Astrophysical Neutrinos from 5 TeV to 10 PeV.

Physical review letters·2026
Same author

Oral Pain and Alzheimer's Disease: Prospective Cohort and Cross-Sectional Analyses.

Journal of dental research·2026
Same author

[Research progress in dental pulp assessment and diagnosis systems for pulpitis].

Zhonghua kou qiang yi xue za zhi = Zhonghua kouqiang yixue zazhi = Chinese journal of stomatology·2025
Same author

Search for Extremely-High-Energy Neutrinos and First Constraints on the Ultrahigh-Energy Cosmic-Ray Proton Fraction with IceCube.

Physical review letters·2025
Same author

Antithrombotic Effect of Ginkgo Biloba Extract: A Study Based on Network Pharmacological Analysis and In vivo Experiments.

Nigerian journal of clinical practice·2025

Related Experiment Video

Updated: May 26, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Trastuzumab treatment in multiple lines: current data and future directions.

M Pegram1, J Liao

  • 1University of Miami Sylvester Comprehensive Cancer Center, Miami, FL 33136, USA. MPegram@med.miami.edu

Clinical Breast Cancer
|December 14, 2011
PubMed
Summary

Continuing trastuzumab beyond disease progression in human epidermal growth factor receptor 2-positive (HER2-positive) metastatic breast cancer (MBC) shows clinical benefit. Evidence suggests improved response rates and survival outcomes, supporting its use in subsequent treatment regimens.

More Related Videos

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Related Experiment Videos

Last Updated: May 26, 2026

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
08:59

Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down

Published on: December 11, 2017

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody
07:36

Analyzing Tumor and Tissue Distribution of Target Antigen Specific Therapeutic Antibody

Published on: May 16, 2020

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

Area of Science:

  • Oncology
  • Medical Research

Background:

  • Trastuzumab is a standard first-line treatment for HER2-positive metastatic breast cancer (MBC).
  • The efficacy of continuing trastuzumab after disease progression remains an area of investigation.

Purpose of the Study:

  • To review existing literature on the clinical utility of continuing trastuzumab beyond disease progression in HER2-positive MBC.
  • To evaluate response rates and survival outcomes in patients receiving trastuzumab beyond progression.

Main Methods:

  • Literature review of retrospective, observational, and prospective non-randomized studies.
  • Analysis of data from two recent prospective randomized phase III trials.

Main Results:

  • Retrospective and observational data suggest clinical benefit from continuing trastuzumab beyond progression.
  • Patients continuing trastuzumab showed superior response rates and survival outcomes.
  • Randomized trials demonstrate significantly prolonged progression-free survival when trastuzumab is added post-progression.

Conclusions:

  • Emerging evidence supports the clinical utility of continuing trastuzumab-based therapy beyond progression in HER2-positive MBC.
  • This approach aligns with National Comprehensive Cancer Network recommendations.
  • Future strategies may involve sequential use of trastuzumab with other targeted therapies for HER2-positive MBC.